Hypoproteinemia is an independent risk factor for the prognosis of severe COVID-19 patients

Liu Lin,† Kaiyuan Hu,† Shujiang Cai,‡ Xilong Deng,¶ Xinning Shao,† Ying Liang,† Jigang Wang,‡§ Tianyu Zhong,¶¶ Zhongwei Hu,†¶ and Ming Lei†,*

†Department of Nephrology, ‡Department of Critical Care Medicine, and §Gastroenterology, Guangzhou Eighth People’s Hospital, Guangzhou Medical University, No. 8, Huaying Road, Guangzhou, Guangzhou 510060, China
‡Department of Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, No. 16, Nankaiqiao, Dongzhimennei Ave, Beijing 100700, China
§Department of Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Gannan Medical University, No. 1, Hexie Road, Ganzhou, Jiangxi 341000, China
¶Department of Laboratory Medicine, First Affiliated Hospital of Gannan Medical University, No. 23, Qingnian Road, Ganzhou, Jiangxi 341000, China

(Received 8 May, 2020; Accepted 29 May, 2020; Published online 6 August, 2020)

Severe patients of the coronavirus disease 2019 (COVID-19) may progress rapidly to critical stage. This study aimed to identify factors useful for predicting the progress. 33 severe COVID-19 patients at the intensive care unit were included in this study. During treatment, 13 patients deteriorated and required further treatment for supporting organ function. The remaining 20 patients alleviated and were transferred to the general wards. The multivariate COX regression analyses showed that hypoproteinemia was an independent risk factor associated with deterioration of severe patients (HR, 0.763; 95% CI, 0.596 to 0.978; p = 0.033). The restricted cubic spline indicated that when HR = 1, the corresponding value of albumin is 29.6 g/L. We used the cutoff of 29.6 g/L to divide these patients. Kaplan–Meier curves showed that the survival rate of the high-albumin group was higher than that of the low-albumin group. Therefore, hypoproteinemia may be an independent risk factor to evaluate poor prognosis of severely patients with COVID-19, especially when albumin levels were below 29.6 g/L.

Key Words: COVID-19, albumin, prognosis, nutrition

The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2), has become a pandemic. As of July 1, 2020, 10.6 million cases of COVID-19 and 0.52 million coronavirus 2 (SARS-CoV-2), has become a pandemic. As of

Participants. This was a retrospective single-center study. It included 33 severely patients with COVID-19 infection treated at the intensive care unit of Guangzhou Eighth People’s Hospital from January 20, 2020 to February 23, 2020. Diagnosis of COVID-19 pneumonia and clinical classification were made according to the new coronavirus pneumonia diagnosis and treatment plan (trial version 6) developed by the National Health Committee of the People’s Republic of China (http://www.nhc.gov.cn/). The clinical classifications are as follows: (1) mild, involving mild clinical symptoms and no evidence of pneumonia on imaging; (2) common, involving fever, respiratory tract issues, and other symptoms, imaging shows pneumonia; (3) severe, any of the following: a) respiratory distress, respiratory rate ≥30 beats/min; b) in the resting state, mean oxygen saturation ≤93%; c) arterial blood oxygen partial pressure/oxygen concentration ≤300 mmHg (1 mmHg = 0.133 kPa), and (4) critical, any one of the following conditions: a) respiratory failure requiring mechanical ventilation; b) shock; c) ICU admission due to combined organ failure.

Baseline data collection. All of the patients were collected upper respiratory tract swab samples at admission which were stored in virus transport medium and transported to the Guangdong CDC for laboratory diagnosis. Epidemiological history, comorbidity, vital signs, and symptoms were recorded in detail, and various laboratory tests, including lactate dehydrogenase, creatine kinase assay, plasma albumin, blood routine, and C-reactive protein, were conducted. We also collected therapeutic measures, including oxygen therapy, use of antibiotics, fluid support (more than 1,000 ml/d), nutritional support, and application of glucocorticoids.

Study outcome. The primary outcome was that the patients progressed to critical illness or alleviated and were transferred to general ward.

Statistical analysis. Categorical variables were presented as number (%) and continuous variables were presented as mean (interquartile range). We compared the differences between the two groups with the t test, Fisher’s exact test, or Mann–Whitney U test. COX regression was used to select independent risk factors that affect outcomes. The corresponding albumin value when HR = 1 was found by the restricted cubic spline, and the patients were divided into the high-albumin group and the low-albumin group according to this cut-off. Kaplan–Meier curve analysis was used to determine whether there was any statistically significant difference in survival rate between the two groups. Statistical analyses were performed using SPSS, ver. 22.0, and R software (ver. R-3.5.2, www.r-project.org). P value <0.05 was considered statistically significant.

These authors contributed equally to this work.
*To whom correspondence should be addressed.
E-mail: gz8hlmsn@126.com (ML); gz8hhzw@126.com (ZH); zhongtianyu@gmail.com. (TZ)
Results

Baseline data of patients. A total of 33 patients were included in this study, all of whom received intensive care in the ICU. There were 22 males (66.7%) and 11 females (33.3%), with a median age of 59 years (51.0–69.5 years). Twenty-four (72.7%) patients were suffering from basic diseases, including hypertension, diabetes, cardiovascular disease, and tumor. Additionally, the main clinical symptoms were fever, cough, shortness of breath, and diarrhea. The time from onset to treatment was 0–8 days (Table 1).

All of the patients were treated for more than 2 weeks. By February 23, 2020, 13 of the 33 patients (39.4%) had deteriorated after admission to ICU, requiring endotracheal intubation, CRRT, or ECMO treatment, and no deaths were observed. The remaining 20 patients (60.6%) became better after comprehensive treatment, such as high-concentration oxygen therapy, and were transferred to the general wards. The median time from onset to diagnosis of severe illness in 33 patients was 8 days (6.5–10.5 days) (Table 1).

The median albumin value was 30.1 g/L (27.9–31.3) in all patients, 27.7 g/L (26.2–29.3) in the worsening group, and 31.0 g/L (29.9–31.6) in the improving group (Table 2). Associations with albumin level and prognosis in patients with COVID-19.

Univariate COX regression analysis disclosed that the degree of pulmonary injury, oxygenation index, serum creatinine, urea nitrogen, leukocyte, uric acid, and albumin were associated with the prognosis of COVID-19 patients. All patients were followed up for 2 months after discharge.
associated with the prognosis of severely patients (Table 3). Multivariate COX regression analysis was performed on the significant variables in univariate COX regression analysis, suggesting that only albumin level was positively correlated to the prognosis of severe patients (HR, 0.763; 95% CI, 0.596–0.978; \( p = 0.033 \)) (Table 4). The low level of the albumin shows the high risk of this disease. RCS analysis showed that when HR reached 1, the corresponding value of albumin was 29.6 g/L (Fig. 1). At the boundary of 29.6 g/L, the patients were divided into a high albumin group and a low albumin group. The Kaplan–Meier curve suggested that the high albumin group indicated better survival than the low albumin group (Fig. 2).

**Discussion**

COVID-19 has spread throughout the world. Once the disease progresses to respiratory failure and requires ventilator assisted ventilation, the case fatality rate can reach 50%. Finding a way to reduce the progress of severely patients to critical is one of the principal goals of ICU treatment. This study showed that the median time from onset to progression to severe disease was 8 days (6.5–10.5 days). Four patients had mild symptoms at onset (presenting with low fever and mild cough), but they progressed to severe disease within 4 days. It is important to identify the risk factors for the disease progression in severely patients.

To this end, clinical manifestation, laboratory examination, and treatment data were assessed in the analysis. Univariate COX regression analysis suggested the degree of lung involvement, oxygenation index, urea nitrogen, creatinine, uric acid, albumin, and WBC were all statistically significant. The multivariable COX regression analysis to these factors indicated that albumin level was an independent risk factor for severe patients to predict the disease progression. We reviewed the clinical data of 33 patients and found that 30 cases (90.9%) had hypoalbuminemia (as indicated by local laboratory examination, under 35 g/L diagnosis hypoalbuminemia), according to the interrogation and auxiliary examination. All of 33 patients showed no evidence of liver cirrhosis, nephrotic syndrome, or chronic wasting disease. The albumin level was significantly lower in the 13 patients with advanced disease who required ventilator-assisted ventilation than in the control group. Hypoproteinemia was found to be an independent predictor of mortality.\(^{4–8}\) In the ICU, the incidence of hypoproteinemia was 40–50\%.\(^{9}\) Hypoproteinemia can lead to deterioration of immune function, changes in colloid osmotic pressure, coagulation disorders, and decrease of the efficacy of certain antibiotics\(^{10–13}\) thus increasing the incidence of poor prognosis in patients. These patients with COVID-19 which is a

| Table 3. Univariate COX regression analysis |
|-----------------------------|----------|
| Factors                  | \( p \)  |
| CT Scan                  | 0.004    |
| Oxygenation index        | 0.002    |
| Creatinine               | 0.002    |
| Urea nitrogen            | 0.001    |
| White blood cell         | 0.015    |
| Uric acid                | 0.009    |
| Albumin                  | <0.001   |

| Table 4. Multivariate COX regression analysis |
|-----------------------------|----------|
| Factors                  | HR (95% CI) | \( p \)  |
| CT Scan                  | 0.845    |
| One lung is involved      | 33,988.00 (0, 2.245E+156) | 0.953    |
| Both lungs are involved   | 12,464.47 (0, 8.101E+155) | 0.958    |
| Oxygenation index         | 0.982 (0.964, 1.000) | 0.051    |
| Creatinine               | 0.995 (0.969, 1.022) | 0.7      |
| Urea nitrogen            | 1.020 (0.713, 1.459) | 0.913    |
| White blood cell         | 1.422 (0.921, 2.195) | 0.112    |
| Uric acid                | 1.004 (0.996, 1.013) | 0.295    |
| Albumin                  | 0.763 (0.596, 0.978) | 0.033    |

HR, hazard ratio; CI, confidence interval.

**Fig. 1.** Relationship between albumin and critical ill patients. Cutoff = 29.6. HR, hazard ratio.
new acute respiratory infectious disease, showed obvious hypoproteinemia. Meanwhile, the incidence rate of hypoproteinemia in those patients was significantly higher than other patients in the ICU, suggesting that there is a special reason for the occurrence of hypoproteinemia in COVID-19 patients. To our knowledge, this is the first report that the hypoproteinemia is correlated to the prognosis of COVID-19 patients.

The high incidence of hypoproteinemia in COVID-19 patients implicated that most patients were in a state of protein malnutrition. The possible reasons for this are as follows: first, the digestive system, like the respiratory system, is made up of important target organs. One study found that the esophagus and ileum epithelium of the new coronavirus to be predisposing risk factors. Another study found the virus to be present in the feces of patients with nucleic acid. Some patients have diarrhea and gastrointestinal symptoms, including nausea and anorexia, which affect food intake and absorption, leading to malnutrition and hypoproteinemia. Second, hypoxia is an important initiator of pathophysiological changes in patients with COVID-19. After hypoxia, blood flow is redistributed, resulting in ischemia and hypoxia of the gastrointestinal tract earlier than in other organs. Severe COVID-19 patients have a long course of disease and are vulnerable to bacterial infection, which increases the consumption of protein and heat energy and leads to a negative nitrogen balance. Additionally, mental issues (anxiety and depression) and side effects of antiviral drugs, are prevalent in COVID-19 patients, resulting in poor appetite and reduced food intake. In summary, COVID-19 is more likely to cause protein malnutrition than other infectious diseases, and this malnutrition will further impair the immune function of patients, thus promoting the deterioration of the patients’ condition.

Currently, there are dietary recommendations for COVID-19 infection patients in China. However, in the clinical settings, especially in areas with more patients, owing to the relative lack of medical resources or the lack of participation and intervention of clinical dietitians, there are few nutrition monitoring intervention measures available for patients with severe COVID-19. Nutritional intervention is especially likely to be skipped for patients who are serious ill but still conscious and able to eat independently. In this study, patients who had undergone tracheal intubation accounted for only 54.5% of the patients who received nutritional intervention mostly consisted of small doses of intravenous amino acids and glucose. Statistical analysis did not indicate that the nutritional support based on the current regimen could speed up the recovery of COVID-19 patients. One possible explanation is that the current nutritional support was not able to be quantified and the uptake of energy and proteins in patients was not enough, which might result in the minimal effect on patient recovery.

In summary, hypoproteinemia was prevalent in patients with COVID-19 who were treated in the ICU and it was an independent risk factor for the progression to critical condition. We suggested that in the early stage of the disease, especially when the albumin level of patients was under 29.6 g/L, nutritional assessment and gastrointestinal dysfunction assessment should be conducted, and reasonable nutritional intervention measures should be taken according to the assessments. The deficiency of this study was that it included only a small number of cases and was a single-center study. At the same time, other indicators of nutritional status assessment were lacking, which makes it difficult to describe the incidence and characteristics of hypoproteinemia in severely patients with COVID-19 in a more comprehensive way. Due to time constraints, the end point of treatment was not observed. Prospective studies are still needed to establish the effect of enteral or parenteral nutritional support on the prognosis of patients infected with COVID-19.

Conclusions

Albumin level was found to be a useful prognostic factor evaluating the prognosis for severely patients with COVID-19 pneumonia. Clinicians should be aware of the importance of the albumin level in COVID-19 patients and provide nutritional assessment and support at an early stage to reduce the incidence of critical illness.

Acknowledgments

We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript. This work was supported by the National Natural Science Foundation of China (81702580) and by the Medical Scientific Research Foundation of Guangdong Province of China (A2019296).

Conflict of Interest

No potential conflicts of interest were disclosed.
References

1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708–1720.

2. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8: 475–481.

3. Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol 2020; 53: 404–412.

4. Li T, Zhang Y, Gong C, et al. Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China. Eur J Clin Nutr 2020; 74: 871–875.

5. Gong J, Ou J, Qiu X, et al. A tool to early predict severe corona virus disease 2019 (COVID-19): a multicenter study using the risk nomogram in Wuhan and Guangdong, China. Clin Infect Dis 2020; ciaa443.

6. Arques S, Roux E, Sbragia P, Gelisse R, Pieri B, Ambrosi P. Usefulness of serum albumin concentration for in-hospital risk stratification in frail, elderly patients with acute heart failure. Insights from a prospective, monocenter study. Int J Cardiol 2018; 125: 265–267.

7. Menon V, Greene T, Wang X, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68: 766–772.

8. Ulldemolins M, Roberts JA, Rello J, Peterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011; 50: 99–110.

9. Schleibinger M, Steinbach CL, Töpper C, et al. Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients. Br J Clin Pharmacol 2015; 80: 525–533.

10. Enokiya T, Muraki Y, Iwamoto T, Okuda M. Changes in the pharmacokinetics of teicoplanin in patients with hyperglycaemic hypoalbuminaemia: impact of albumin glycosylation on the binding of teicoplanin to albumin. Int J Antimicrob Agents 2015; 46: 164–168.

11. Cohen S, Danzaki K, Maclver NJ. Nutritional effects on T-cell immunometabolism. Eur J Immunol 2017; 47: 225–235.

12. Alwarawrah Y, Kieran K, Maclver NJ. Changes in nutritional status impact immune cell metabolism and function. Front Immunol 2018; 9: 1055.

13. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020; 14: 185–192.

14. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2018; 382: 929–936.

15. Zhu Q, He G, Wang J, Chen W. Protective effects of fenofibrate against acute lung injury induced by intestinal ischemia/reperfusion in mice. Sci Rep 2016; 6: 22044.

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.